GlassScriptPhysician profile
William Gerard Hebert
NPI 1598834491
$2,273.20
in general payments reported to CMS, 2019-2025
24 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $107 · 2021: $519 · 2022: $285 · 2023: $472 · 2024: $267 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $580.95 | 2021-2025 | |
| Glaxosmithkline, LLC. | $487.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $419.64 | 2019-2025 | |
| Esperion Therapeutics, INC. | $147.06 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $118.27 | 2019-2021 | |
| Lilly USA, LLC | $89.66 | 2020-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $49.10 | 2019 | |
| Allergan, INC. | $48.78 | 2019 | |
| Amgen INC. | $44.51 | 2020-2021 | |
| Antares Pharma, INC. | $37.18 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $36.06 | 2021 | |
| Abbott Laboratories | $33.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $29.66 | 2022-2023 | Breztri |
| Alfasigma USA, INC. | $19.77 | 2022 | |
| Lundbeck LLC | $18.98 | 2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.28 | 2024 | Jardiance |
| Novo Nordisk INC | $15.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.92 | 2019 | |
| Philips North America LLC | $14.46 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.49 | 2019 | |
| Merck Sharp & Dohme LLC | $12.27 | 2022 | |
| Astellas Pharma US INC | $11.18 | 2021 | |
| Phathom Pharmaceuticals, INC. | $10.30 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $5.68 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.